ERYTHROID DIFFERENTIATION AND POLY (ADP-RIBOSE) SYNTHESIS IN FRIEND LEUKEMIA CELLS

Nicotinamide, a specific inhibitor of poly (ADP-ribose) synthetase, was found to be a moderate inducer of hemoglobin synthesis in Friend erythroid leukemia cells (FLC). Therefore, the effect of other inducers, such as dimethyl sulfoxide (DMSO), hexamethylene-bisacetamide (HMBA), and butyrate, on pol...

Full description

Saved in:
Bibliographic Details
Published inGANN Japanese Journal of Cancer Research Vol. 70; no. 1; pp. 37 - 46
Main Authors ISHIZAWA, Minoru, MORIOKA, Kiyokazu, TANAKA, Kiyoko, NOKUO, Tadashi, ONO, Tetsuo
Format Journal Article
LanguageEnglish
Published Japan The Japanese Cancer Association 01.01.1979
Subjects
Online AccessGet full text
ISSN0016-450X
DOI10.20772/cancersci1959.70.1_37

Cover

More Information
Summary:Nicotinamide, a specific inhibitor of poly (ADP-ribose) synthetase, was found to be a moderate inducer of hemoglobin synthesis in Friend erythroid leukemia cells (FLC). Therefore, the effect of other inducers, such as dimethyl sulfoxide (DMSO), hexamethylene-bisacetamide (HMBA), and butyrate, on poly (ADP-ribose) synthesis was examined. The extent of poly (ADP-ribose) synthesis in nuclei of FLC treated with DMSO or HMBA began to decrease before many phenotypic changes including hemoglobin production and reached 30∼50% of the level of nontreated control when the cells enter the stationary phase. FLC variants unresponsive to HMBA or DMSO did not exhibit as low an activity of poly (ADP-ribose) synthesis as their parent cells did by treatment with these inducers. In contrast, butyrate stimulated poly (ADP-ribose) synthesis transiently but distinctly (about 50%) at an early stage of culture (6∼24hr), but suppressed it at a later stage. Neither the cell growth nor degradation of poly (ADP-ribose) is correlated with the effect of inducers. These results suggest that the level of poly (ADP-ribose) synthesis is correlated with the differentiation of FLC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0016-450X
DOI:10.20772/cancersci1959.70.1_37